Christoph Patrik Beier

Prof. Dr. Christoph Patrik Beier

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DBDagmar Beier
Dagmar Beier
PHPeter Hau
Peter Hau
MPMartin Proescholdt
Martin Proescholdt
ALAnnette Lohmeier
Annette Lohmeier
JWJörg Wischhusen
Jörg Wischhusen
CBChristoph Patrik Beier
Christoph Patrik Beier
Although glioblastomas show the same histologic phenotype, biological hallmarks such as growth and differentiation properties vary considerably between individual cases. To investigate whether different subtypes of glioblastomas might originate from different cells of origin, we cultured tumor cells from 22 glioblastomas under medium conditions favoring the growth of neural and cancer stem cells (CSC). Secondary glioblastoma (n = 7)–derived cells did not show any growth in the medium used, suggesting the absence of neural stem cell–like tumor cells. In contrast, 11/15 primary glioblastomas contained a significant CD133+ subpopulation that displayed neurosphere-like, nonadherent growth and asymmetrical cell divisions yielding cells expressing markers characteristic for all three neural lineages. Four of 15 cell lines derived from primary glioblastomas grew adherently in vitro and were driven by CD133− tumor cells that fulfilled stem cell criteria. Both subtypes were similarly tumorigenic in nude mice in vivo. Clinically, CD133− glioblastomas were characterized by a lower proliferation index, whereas glial fibrillary acidic protein staining was similar. GeneArray analysis revealed 117 genes to be differentially expressed by these two subtypes. Together, our data provide first evidence that CD133+ CSC maintain only a subset of primary glioblastomas. The remainder stems from previously unknown CD133− tumor cells with apparent stem cell–like properties but distinct molecular profiles and growth characteristics in vitro and in vivo. [Cancer Res 2007;67(9):4010–5]

1 July 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
KKKaroline Knudsen
Karoline Knudsen
TFTatyana D Fedorova
Tatyana D Fedorova
AHAllan K Hansen
Allan K Hansen
MSMichael Sommerauer
Michael Sommerauer
MOMarit Otto
Marit Otto
PBPer Borghammer
Per Borghammer

1 January 2011 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
DBDagmar Beier
Dagmar Beier
JSJoerg B Schulz
Joerg B Schulz
CBChristoph Patrik Beier
Christoph Patrik Beier
Glioblastomas (GBM) are a paradigm for the investigation of cancer stem cells (CSC) in solid malignancies. The susceptibility of GBM CSC to standard chemotherapeutic drugs is controversial as the existing literature presents conflicting experimental data. Here, we summarize the experimental evidence on the resistance of GBM CSC to alkylating chemotherapeutic agents, with a special focus on temozolomide (TMZ). The data suggests that CSC are neither resistant nor susceptible to chemotherapy per se. Detoxifying proteins such as O6-methylguanine-DNA-methyltransferase (MGMT) confer a strong intrinsic resistance to CSC in all studies. Extrinsic factors may also contribute to the resistance of CSC to TMZ. These may include TMZ concentrations in the brain parenchyma, TMZ dosing schemes, hypoxic microenvironments, niche factors, and the re-acquisition of stem cell properties by non-stem cells. Thus, the interaction of CSC and chemotherapy is more complex than may be expected and it is necessary to consider these factors in order to overcome chemoresistance in the patient.

15 July 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
DBDagmar Beier
Dagmar Beier
SRStefanie RöhRl
Stefanie RöhRl
DPDeepu R. Pillai
Deepu R. Pillai
SSStefanie Schwarz
Stefanie Schwarz
LKLeoni Kunz-Schughart
Leoni Kunz-Schughart
CBChristoph Patrik Beier
Christoph Patrik Beier
The prognosis of patients suffering from glioblastoma (GBM) is dismal despite multimodal therapy. Although chemotherapy with temozolomide may contain tumor growth for some months, invariable tumor recurrence suggests that cancer stem cells (CSC) maintaining these tumors persist. We have therefore investigated the effect of temozolomide on CD133+ and CD133− GBM CSC lines. Although differentiated tumor cells constituting the bulk of all tumor cells were resistant to the cytotoxic effects of the substance, temozolomide induced a dose- and time-dependent decline of the stem cell subpopulation. Incubation with sublethal concentrations of temozolomide for 2 days completely depleted clonogenic tumor cells in vitro and substantially reduced tumorigenicity in vivo. In O6-methylguanine-DNA-methyltransferase (MGMT)–expressing CSC lines, this effect occurred at 10-fold higher doses compared with MGMT-negative CSC lines. Thus, temozolomide concentrations that are reached in patients were only sufficient to completely eliminate CSC in vitro from MGMT-negative but not from MGMT-positive tumors. Accordingly, our data strongly suggest that optimized temozolomide-based chemotherapeutic protocols might substantially improve the elimination of GBM stem cells and consequently prolong the survival of patients. [Cancer Res 2008;68(14):5706–15]

28 February 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CLClaudio Lottaz
Claudio Lottaz
DBDagmar Beier
Dagmar Beier
KMKatharina Meyer
Katharina Meyer
PKPraveen Kumar
Praveen Kumar
AHAndreas Hermann
Andreas Hermann
CBChristoph Patrik Beier
Christoph Patrik Beier
Glioblastoma multiforme (GBM) is paradigmatic for the investigation of cancer stem cells (CSC) in solid tumors. Growing evidence suggests that different types of CSC lead to the formation of GBM. This has prompted the present comparison of gene expression profiles between 17 GBM CSC lines and their different putative founder cells. Using a newly derived 24-gene signature, we can now distinguish two subgroups of GBM: Type I CSC lines display “proneural” signature genes and resemble fetal neural stem cell (fNSC) lines, whereas type II CSC lines show “mesenchymal” transcriptional profiles similar to adult NSC (aNSC) lines. Phenotypically, type I CSC lines are CD133 positive and grow as neurospheres. Type II CSC lines, in contrast, display (semi-)adherent growth and lack CD133 expression. Molecular differences between type I and type II CSC lines include the expression of extracellular matrix molecules and the transcriptional activity of the WNT and the transforming growth factor-β/bone morphogenetic protein signaling pathways. Importantly, these characteristics were not affected by induced adherence on laminin. Comparing CSC lines with their putative cells of origin, we observed greatly increased proliferation and impaired differentiation capacity in both types of CSC lines but no cancer-associated activation of otherwise silent signaling pathways. Thus, our data suggest that the heterogeneous tumor entity GBM may derive from cells that have preserved or acquired properties of either fNSC or aNSC but lost the corresponding differentiation potential. Moreover, we propose a gene signature that enables the subclassification of GBM according to their putative cells of origin. Cancer Res; 70(5); 2030–40

1 August 2009 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
FBFusun Baumann
Fusun Baumann
PLPetra Leukel
Petra Leukel
ADAnett Doerfelt
Anett Doerfelt
CBChristoph Patrik Beier
Christoph Patrik Beier
KDKatja Dettmer
Katja Dettmer
Peter HauPeter Hau
Peter Hau
Lactate dehydrogenase type A (LDH-A) is a key metabolic enzyme catalyzing pyruvate into lactate and is excessively expressed by tumor cells. Transfor